Journal
ANTIVIRAL RESEARCH
Volume 190, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2021.105075
Keywords
SARS-CoV-2; Chebulagic acid; Punicalagin; 3CLpro; Allosteric inhibitor
Categories
Funding
- Key R&D Project in Shandong Province, China [2020CXGC010505]
- Shandong Provincial Natural Science Foundation, China [ZR2020MH383]
- Social Benefiting Technology Program of Qingdao [21-1-4-rkjk-15nsh]
Ask authors/readers for more resources
The study found that chebulagic acid and punicalagin can inhibit the replication of SARS-CoV-2 virus in cells, and reduce virus-induced plaque formation at noncytotoxic concentrations, by regulating the enzymatic activity of viral protease as allosteric regulators.
The emerging SARS-CoV-2 infection is the cause of the global COVID-19 pandemic. To date, there are limited therapeutic options available to fight this disease. Here we examined the inhibitory abilities of two broad-spectrum antiviral natural products chebulagic acid (CHLA) and punicalagin (PUG) against SARS-CoV-2 viral replication. Both CHLA and PUG reduced virus-induced plaque formation in Vero-E6 monolayer at noncytotoxic concentrations, by targeting the enzymatic activity of viral 3-chymotrypsin-like cysteine protease (3CL(pro)) as allosteric regulators. Our study demonstrates the potential use of CHLA and PUG as novel COVID-19 therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
